Aging, Alzheimer's Disease, Biomarker, Neuroimaging


Pathophysiology characterization and early detection of Alzheimer's disease

We aim to investigate the pathological features and evolutionary patterns of Alzheimer's disease (AD), especially the asymptomatic AD. We try to find clues from the clinical data, and conduct animal and cellular experiments to validate the phenomena and elucidate the underlying molecular mechanism, using multimodal molecular imaging, biomarkers detection, and biochemical methods. Furtherly, we try to find effective intervention solutions.


大湾区老年脑健康计划 - Greater-Bay-Area Healthy Aging Brain Study


In order to investigate the AD-related pathologies changes and establish an effective prevention scheme for elderly adults who have AD pathologies in China’s aging population, we are recruiting elderly adults age 55 and older to establish the Greater-Bay-Area Healthy Aging Brain Study(GHABS) in Shenzhen Bay Laboratory. GHABS participants will undergo clinical neuropsychological assessments, blood collection, PET and MRI imaging, and receive drug or Non-Drug AD clinical trials. The GHABS project aims to: 1) study the risk factors of Aβ and tau aggregation in early stages of AD among China’s aging population; 2) study the effect of Aβ and tau pathologies upon neurodegeneration and cognitive decline in both Aβ negative (Aβ-) and Aβ positive (Aβ+) elderly adults; 3) identify novel approaches and techniques for early detection of AD and provides a reference for the target brain region and appropriate time window for anti-AD treatment.






The Alzheimer’s Disease Neuroimaging Initiative (ADNI)

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a longitudinal multicenter study designed to develop clinical, imaging, genetic, and biochemical biomarkers for the early detection and tracking of Alzheimer's disease (AD). Since its launch more than a decade ago, the landmark public-private partnership has made major contributions to AD research, enabling the sharing of data between researchers around the world. Three overarching goals of the ADNI study are: 1, To detect AD at the earliest possible stage (pre-dementia) and identify ways to track the disease’s progression with biomarkers. 2, To support advances in AD intervention, prevention, and treatment through the application of new diagnostic methods at the earliest possible stages (when intervention may be most effective). 3, To continually administer ADNI’s innovative data-access policy, which provides all data without embargo to all scientists in the world. HISTORY ADNI began in 2004 under the leadership of Dr. Michael W. Weiner, funded as a private-public partnership with $27 million contributed by 20 companies and two foundations through the Foundation for the National Institutes of Health and $40 million from the National Institute on Aging. The initial five-year study (ADNI-1) was extended by two years in 2009 by a Grand Opportunities grant (ADNI-GO), and in 2011 and 2016 by further competitive renewals of the ADNI-1 grant (ADNI-2, and ADNI-3, respectively).